NCCN Quick Guide™ | Myelodysplastic Syndromes

1 of 2 NCCN QUICK GUIDE tm Myelodysplastic Syndromes, 2018 This NCCNQUICK GUIDE tm sheet summarizes key points from the complete NCCN Guidelines for Patients ® : Myelodysplastic Syndromes . T hese guidelines explain which tests and treatments are recommended by experts in cancer. To view and download the guidelines, visit NCC N.or g/patients or, to order printed copies, visit What is MDS (myelodysplastic syndromes)? MDS is a group of cancers that affect blood cells in the bloodstream and bone marrow. In MDS, the bone marrow isn’t able to make enough normal, healthy blood cells that the body needs. 9 Do I have MDS? „„ MDS often causes a low number of one or more types of blood cells. Another key feature is that the defective blood cells have an abnormal size, shape, or look. This is called dysplasia. 12 „„ Blood tests are done along with other initial tests to help diagnose MDS. 16 „„ Your bone marrow must be tested to confirm if you have MDS. 18 How do doctors group MDS for treatment planning? „„ Prognostic scoring is how doctors rate the severity of MDS and assess outlook (prognosis). 23 „„ The risk score describes how slow or fast MDS may grow and progress to AML ( a cute m yeloid l eukemia) if not treated. The risk score is used to assign the risk group. „„ Doctors use the risk group to decide which treatment to use and when. „„ Supportive care is an important part of treatment for all patients with MDS. It may be the only treatment needed for lower-risk MDS. It is also given with other treatments for higher- risk MDS. 28 „„ Lower-risk MDS is more likely to grow slowly and may not progress to AML for a long time. 41 „„ Higher-risk MDS is more likely to grow faster and progress to AML in a shorter amount of time. NCCN Guidelines for Patients ® Page Number Ü NCCN GUIDELINES FOR PATIENTS ® NCCN QUICK GUIDE tm Myelodysplastic Syndromes 2018